@article{40af763234f947c99ce73ba1b476f521,
title = "Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso G{\'o}mez de Lia{\~n}o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation",
author = "\{van Dijk\}, Nick and \{G{\'o}mez de Lia{\~n}o Lista\}, Alfonso and Bernadett Szabados and Thomas Powles and \{van der Heijden\}, \{Michiel S.\}",
note = "Funding Information: Conflicts of interest: Michiel S. van der Heijden has received institutional consultancy fees from AstraZeneca/Medimmune, Roche/Genentech, BMS, Seagen and Merck/MSD, and research funding from BMS, Roche and Astellas. Thomas Powles has received consultancy fees from BMS, Pfizer, Merck/MSD, AstraZeneca, Lilly, Roche/Genentech, and Exelexis, and research funding from AstraZeneca and Roche/Genentech. Alfonso G{\'o}mez de Lia{\~n}o Lista is a consultant for Roche/Genentech; has received honoraria for educational activities from AstraZeneca, BMS, Pfizer, and Roche/Genentech; and has received travel/registration expenses from Pfizer and Roche/Genentech. Nick van Dijk and Bernadett Szabados have nothing to disclose.",
year = "2021",
month = jan,
doi = "10.1016/j.eururo.2020.10.018",
language = "English",
volume = "79",
pages = "e20--e21",
journal = "European urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",
}
SDG 3 Good Health and Well-being